Who Exports Erythromycin from India — 368 Suppliers Behind a $79.7M Market
India's erythromycin export market is supplied by 368 active exporters who collectively shipped $79.7M across 3,939 shipments. MEDOPHARM leads with a 32.0% market share, followed by BDH INDUSTRIES LIMITED and LINCOLN PHARMACEUTICALS LTD. The top 5 suppliers together control 48.9% of total export value, reflecting a moderately competitive market structure.
Top Erythromycin Exporters from India — Ranked by Export Value
MEDOPHARM is the leading erythromycin exporter from India, holding a 32.0% share of the $79.7M market across 3,939 shipments from 368 exporters. The top 5 suppliers — MEDOPHARM, BDH INDUSTRIES LIMITED, LINCOLN PHARMACEUTICALS LTD, S KANT HEALTHCARE LIMITED, MEDREICH LIMITED — collectively control 48.9% of total export value, indicating a competitive market. Individual shares are: MEDOPHARM (32.0%), BDH INDUSTRIES LIMITED (7.1%), LINCOLN PHARMACEUTICALS LTD (3.6%), S KANT HEALTHCARE LIMITED (3.5%), MEDREICH LIMITED (2.7%).
Top Erythromycin Exporters from India
Ranked by export value · 368 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | MEDOPHARM ERYTHROMYCIN STEARATE TABLETS BP 250MGERYTHROMYCIN STEARATE TABLETS BP 250MG - BOXBACTMYCIN SUSP. 100ML (ERYTHROMYCIN BP 1 | $25.5M | 14 | 32.0% |
| 2 | BDH INDUSTRIES LIMITED PHARMACEUTICAL PRODUCTS HARMLESS MEDICINE, ERYTHCINERYTHROMYCIN STEARATE FOR ORAL SUSPENSIOERYTHROMYCIN STEARATE ORAL SUSPENSION 25 | $5.7M | 7 | 7.1% |
| 3 | LINCOLN PHARMACEUTICALS LTD ERYTHROMYCIN STEARATE FOR ORAL SUSPENSIOERYTHROMYCIN STEARATE ORAL SUSPENSION 25ERYTHROMYCIN STEARATE TABLETS BP 500MG U | $2.9M | 4 | 3.6% |
| 4 | S KANT HEALTHCARE LIMITED ERYTHROMYCIN STEARATE TABLETS BP 250MGPHARMACEUTICAL PRODUCTS HARMLESS MEDICINE, ERYTHCINERYTHROMYCIN STEARATE FOR ORAL SUSPENSIO | $2.8M | 20 | 3.5% |
| 5 | MEDREICH LIMITED ERYTHROMYCIN TABLETS BPERYTHROMYCIN TABLETS BP 250MG,ERYTHROMYCIN 250MG GASTRO RESISTANT TABLETS 102219X 2X 14S | $2.1M | 4 | 2.7% |
| 6 | CADILA PHARMACEUTICALS LIMITED PHARMACEUTICALS MEDICINES:ERYTHROMYCIN TPHARMACEUTICALS MEDICINES: ERYTHROMYCIN | $1.4M | 5 | 1.8% |
| 7 | BHARAT PARENTERALS LIMITED ERYTHROMYCIN STEARATE FOR ORAL SUSPENSIOERYTHROMYCIN STEARATE ORAL SUSPENSION 25ERYTHROMYCIN STEARATE TABLETS BP 500MG U | $1.4M | 2 | 1.7% |
| 8 | MEDOPHARM PRIVATE LIMITED ERYTHROMYCIN STEARATE TABLETS BP 250MGERYTHROMYCIN STEARATE TABLETS BP 250MG - BOXBACTMYCIN SUSP. 100ML (ERYTHROMYCIN BP 1 | $1.3M | 2 | 1.6% |
| 9 | BIOMATRIX HEALTHCARE PRIVATE LIMITED ERYTHROMYCIN STEARATE FOR ORAL SUSPENSIOERYTHROMYCIN STEARATE ORAL SUSPENSION 25ERYTHROMYCIN STEARATE TABLETS BP 500MG U | $1.3M | 4 | 1.6% |
| 10 | ANGEL BIOGENICS PRIVATE LIMITED ERYTHROMYCIN 250MG TAB ERYTHROMYCIN 250MERYTHROMYCIN 250MG TABS ERYTHROMYCIN 250 | $1.2M | 2 | 1.6% |
| 11 | CAPLIN POINT LABORATORIES LIMITED | $1.2M | 4 | 1.5% |
| 12 | SIDHAANT LIFE SCIENCES PRIVATE LIMITED | $1.2M | 6 | 1.5% |
| 13 | S K AGE EXPORTS ERYTHROMYCIN STEARATE TABLETS BP 250MGPHARMACEUTICAL PRODUCTS HARMLESS MEDICINE, ERYTHCINERYTHROMYCIN STEARATE FOR ORAL SUSPENSIO | $1.1M | 7 | 1.4% |
| 14 | GLOBELA PHARMA PRIVATE LIMITED BACTMYCIN SUSP. 100ML (ERYTHROMYCIN BP 1BEXTOMAX TABLET ERYTHROMYCINE STEARATE 500MGERYTHROMYCIN STEARATE TABLETS BP 500 MG | $1.1M | 2 | 1.4% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Erythromycin exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| Cadila Pharmaceuticals Limited | Warning Letter, October 2 | Yes, multiple facili | No | Not verified | Received FDA warning letter in October 2019 for violations at Moraiya and Ahmeda |
| Lincoln Pharmaceuticals Limited | Not Listed | Yes, certified in 19 | Yes, certified | Not verified | Received EU GMP certification for Khatraj facility in May 2020. |
| Medopharm Private Limited | Not Listed | Yes, certified in 20 | No | Not verified | WHO-GMP certified as of 2025. |
| S Kant Healthcare Limited | Not Listed | Yes, certified in 20 | No | Not verified | WHO-GMP certified as of 2025. |
| Caplin Point Laboratories Limited | Not Listed | Yes, certified in 20 | No | Not verified | WHO-GMP certified in 2005. |
| Global Pharma Healthcare Private Limited | Not Listed | Yes, certified in 20 | No | Not verified | WHO-GMP certified as of 2025. |
| Medreich Limited | Not Listed | Yes, certified in 20 | No | Not verified | WHO-GMP certified as of 2025. |
| BDH Industries Limited | Not Listed | Yes, certified in 20 | No | Not verified | WHO-GMP certified as of 2025. |
TransData Nexus reviewed the regulatory standing of 8 leading Erythromycin exporters from India. 0 hold US FDA facility approvals, 8 maintain WHO-GMP certification, and 1 are EU GMP compliant. 1 supplier has received FDA regulatory actions — buyers should verify current remediation status before placing orders. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Erythromycin sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as the "Bulk Drug Capital of India," contributes over 40% of the country's bulk drug production. This prominence is supported by a robust infrastructure that includes numerous bulk drug manufacturers and a skilled workforce. The city's pharmaceutical landscape is further enhanced by the Hyderabad Pharma City project, recognized as a National Investment Manufacturing Zone (NIMZ) in December 2019, underscoring its strategic importance.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is renowned for its focus on pharmaceutical formulations. Vadodara, in particular, hosts a significant number of pharmaceutical companies, making it a major hub in the region. This cluster's emphasis on formulations complements the bulk drug production capabilities of other regions, contributing to a comprehensive pharmaceutical supply chain.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad belt serves as a critical export gateway for India's pharmaceutical products. Mumbai's strategic coastal location and well-developed port facilities facilitate efficient international distribution. The region's pharmaceutical industry is characterized by a mix of established companies and emerging players, all benefiting from the logistical advantages and proximity to regulatory bodies.
4Baddi-Nalagarh — Tax Incentive Zone
The Baddi-Nalagarh region in Himachal Pradesh has emerged as a significant pharmaceutical manufacturing zone, largely due to favorable tax incentives. These incentives have attracted numerous pharmaceutical companies, leading to the establishment of a thriving industrial hub. The region's growth underscores the impact of policy measures in shaping industrial landscapes.
5Sourcing Recommendations
- Diversify Supplier Base: While MEDOPHARM dominates Erythromycin exports with a 32.0% share, engaging with other suppliers like BDH INDUSTRIES LIMITED and LINCOLN PHARMACEUTICALS LTD can mitigate supply chain risks.
- Leverage Regional Specializations: Utilize Hyderabad's bulk drug production capabilities for raw materials and Ahmedabad-Vadodara's expertise in formulations to optimize the supply chain.
- Optimize Export Logistics: Capitalize on the Mumbai-Thane-Raigad region's export infrastructure to enhance distribution efficiency and reduce lead times.
- Monitor Policy Changes: Stay informed about tax incentives and regulatory developments in regions like Baddi-Nalagarh to identify cost-saving opportunities and potential shifts in manufacturing dynamics.
By strategically aligning sourcing and distribution efforts with the strengths of India's pharmaceutical clusters, companies can enhance their competitiveness in the global Erythromycin market.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Erythromycin exporters from India
Novartis — Novartis acquires Avidity Biosciences for $12 billion
Novartis announced an agreement to acquire U.S.-based biotech company Avidity Biosciences for approximately $12 billion in cash. This acquisition aims to expand Novartis's portfolio in rare muscle disorders, addressing significant unmet medical needs. IMPACT: This acquisition may lead to increased competition in the pharmaceutical sector, potentially affecting market dynamics for erythromycin exports.
Impact: This acquisition may lead to increased competition in the pharmaceutical sector, potentially affecting market dynamics for erythromycin exports.
Johnson & Johnson — Johnson & Johnson acquires Intra-Cellular Therapies for $14.6 billion
Johnson & Johnson completed the acquisition of Intra-Cellular Therapies, integrating the company into its Innovative Medicine division. This move adds CAPLYTA® (lumateperone), a treatment for bipolar I and II depression and schizophrenia, to Johnson & Johnson's portfolio. IMPACT: The expansion of Johnson & Johnson's neuroscience portfolio may shift focus within the pharmaceutical industry, indirectly influencing erythromycin market trends.
Impact: The expansion of Johnson & Johnson's neuroscience portfolio may shift focus within the pharmaceutical industry, indirectly influencing erythromycin market trends.
Sun Pharmaceutical Industries Limited — Sun Pharma acquires Checkpoint Therapeutics for targeted oncology expansion
Sun Pharma completed its acquisition of Checkpoint Therapeutics, an immunotherapy and targeted oncology company, for $4.10 per share, with additional contingent value rights. This acquisition includes Unloxcyttm, an FDA-approved anti-PD-L1 therapy for advanced cutaneous squamous cell carcinoma. IMPACT: Sun Pharma's expansion into targeted oncology may influence its strategic priorities, potentially affecting its position in the erythromycin export market.
Impact: Sun Pharma's expansion into targeted oncology may influence its strategic priorities, potentially affecting its position in the erythromycin export market.
Common Questions — Erythromycin Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which erythromycin supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, MEDOPHARM leads with 61 recorded shipments worth $25.5M. BDH INDUSTRIES LIMITED (17 shipments) and LINCOLN PHARMACEUTICALS LTD (11 shipments) are also established high-volume exporters.
Q How many erythromycin manufacturers are there in India?
India has 368 active erythromycin exporters with a combined export market of $79.7M across 3,939 shipments to 135 countries. The top 5 suppliers hold 48.9% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for erythromycin from India?
Average FOB unit price: $92.64 per unit, ranging from $0.01 to $89112.90. Average shipment value: $20.2K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 368 verified Indian exporters of Erythromycin ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 3,939 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 135 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
3,939 Verified Shipments
368 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists